CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Travere Therapeutics, Inc.

TVTX
$5.62BMid Cap

Next catalyst

Phase 2March 2027

Sparsentan

Focal Segmental Glomerulosclerosis

Get an email about TVTX's next catalysts

Track Travere Therapeutics (TVTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

3 upcoming, 1 past

Phase 2Next

Sparsentan Phase 2 Est. Readout (EPPIK)

March 2027~Sparsentan67

Primary completion for Sparsentan trial (NCT05003986) in Focal Segmental Glomerulosclerosis

Source
Phase 2

Pegtibatinase Phase 2 Est. Readout

July 2027~Pegtibatinase39

Estimated primary completion for Pegtibatinase trial (NCT03406611) in Homocystinuria. Topline data typically follows completion by weeks to months.

Source
Phase 3

Pegtibatinase Phase 3 Est. Readout (HARMONY)

August 2027~Pegtibatinase70

Estimated primary completion for Pegtibatinase trial (NCT06247085) in Homocystinuria. Topline data typically follows completion by weeks to months.

Source

How TVTX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO385 employees

Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

Drug Pipeline

Frequently asked questions

What is in Travere Therapeutics, Inc.'s drug pipeline?→

CatalystAlert tracks 5 drug candidates in Travere Therapeutics, Inc.'s (TVTX) pipeline across Phase 3, Phase 2. Its lead program is Pegtibatinase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Travere Therapeutics, Inc.'s next FDA catalyst?→

Travere Therapeutics, Inc.'s (TVTX) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TVTX biotech catalysts?→

Add TVTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Travere Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply